Researchers at Columbia University/New York State Psychiatric Institute are conducting an experimental treatment study for pediatric OCD. The study aims to determine whether ketamine, an anesthetic medication, can cause a rapid decrease in OCD symptoms. Eligible participants will receive a free, thorough diagnostic evaluation, and a one-time low dose of intravenous ketamine. Participants will be monitored by clinical staff for two weeks following the ketamine infusion. They can then receive three months of treatment for OCD including medication and/or cognitive-behavioral therapy (CBT) at no cost.

Organization
Columbia University/New York State Psychiatric Institute (NYSPI)
Principal Investigator
Moira Rynn, MD
Eligibility Criteria

Male and female, ages 14-20:

  • Diagnosed with OCD
  • Tried at least two SRI medications and CBT with little or no change in OCD symptoms

Male and female, ages 14-20:

  • Diagnosed with OCD
  • Tried at least two SRI medications and CBT with little or no change in OCD symptoms
Exclusion Criteria

 

Contact
Dylan Braun; 646-774-5793 or braundy@nyspi.columbia.edu
Location
1051 Riverside Drive
State
NY
Study End Date